| Pharmaceutical Information |
| Drug Name |
Bepotastine |
| Drug ID |
BADD_D00252 |
| Description |
Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. |
| Indications and Usage |
For the symptomatic treatment of itchy eyes (caused by IgE-induced mast cell degranulation) due to allergic conjunctivitis. |
| Marketing Status |
approved |
| ATC Code |
Not Available |
| DrugBank ID |
DB04890
|
| KEGG ID |
D09705
|
| MeSH ID |
C108476
|
| PubChem ID |
164522
|
| TTD Drug ID |
D0U5VZ
|
| NDC Product Code |
42672-0100 |
| UNII |
HYD2U48IAS
|
| Synonyms |
bepotastine | betotastine | (S)-4-(4-((4-chlorophenyl)(2-pyridil)methoxy)piperidino)butylic acid monobenzenesulfonate | betotastine besilate | TAU 284 | TAU-284 |
|
| Chemical Information |
| Molecular Formula |
C21H25ClN2O3 |
| CAS Registry Number |
125602-71-3 |
| SMILES |
C1CN(CCC1OC(C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
